July 2021 - Page 2 of 3 - CanadianCannabisWire

TuesdayJul 20, 2021 9:00 am

Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) Leverages Genetic Technology to Produce First-In-Class Medical Grade Cannabis

Science continues to substantiate use of cannabis for pain relief, epileptic seizure control Research suggests strains with optimized cannabinoid profiles are more effective PACR produces premium top-quality strains cultivated using genetics-first approach to optimize cannabinoid profiles Genetic cultivation techniques allow selection for specific growing environments, maximum yields With a growing list of use cases spanning pain relief to seizure control, the medicinal use of cannabis goes back thousands of years (https://cnw.fm/GvpWP). Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), a Canadian cannabis company, leverages a genetics-focused approach to producing premium-quality strains with optimum cannabinoid profiles that are prized among…

MondayJul 19, 2021 11:25 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

XPhyto partners with AGORA t to grow its brand and overall market share The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 AGORA is known for its online marketing, conferences, broadcasting and investor relations services Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp…

FridayJul 16, 2021 9:30 am

New Patent Expands Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Suite to 20 Granted Worldwide (First in Japan)

Drug delivery platform developer Lexaria Bioscience recently received its 20th patent — granted in Japan for beverages with lipophilic active agents The active agents include non-psychoactive cannabinoids and over-the-counter NSAIDS such as ibuprofen and aspirin that target pain and inflammation Lexaria’s DehydraTECH platform transforms drugs into a powder or liquid form that maintains the drug’s efficacy and allows it to be assimilated by the body more rapidly than normal oral ingestion of pills The company will also announce the latest results from six key R&D projects focusing on concentration levels, tolerability and avoidance of incidental new molecular entities (“NMEs”) soon…

ThursdayJul 15, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Commercial Success with its Drug Delivery Technology

Lexaria is making progress with research on its DehydraTECH drug delivery technology Advanced 2nd-generation DehydraTECH 2.0 formulations utilized in ongoing hypertension studies The company intends to monetize its technology for commercial use Its quest for commercial success also follows its move to delist from the Canada Securities Exchange (“CSE”) to focus on the Nasdaq listing Lexaria Bioscience (NASDAQ: LEXX) continues to innovate with its DehydraTECH(TM) drug-delivery technology. It is constantly collaborating with research institutions and businesses to identify other new ways to improve its technology. So far, advanced DehydraTECH 2.0 formulations are already being used by the company in ongoing…

WednesdayJul 14, 2021 9:06 am

Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) Positioned to Profit From Shifting Consumer Preferences For Legal Market, High-Quality Strains, Brand Recognition

Market for legal cannabis continues to mature, British Columbia government to allow cannabis home delivery starting July 15, 2021 PACR produces premium top-quality strains cultivated using genetics-first approach, catalog features 350 tested cultivars and 50 super-elite strains prized for unique cannabinoid profiles PACR leverages branding power through recent acquisition of legendary Lords of Grasstown brand inspired by Pacific Northwest motorcycle culture As the market for cannabis continues to shift towards legal avenues for product procurement, Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), a Canada-based cannabis company, continues to position itself for an increased market share through a…

TuesdayJul 13, 2021 10:15 am

BevCanna Enterprises Inc.’s (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) TRACE Line of Products Addresses Declining Minerals in Food Supply

Soil depletion causing mineral loss in food supply BevCanna’s TRACE line of products address issue through proprietary plant-based formula rich in iron, magnesium, calcium, potassium Company recently signed distribution agreement to reach target markets in New York, Chicago, California BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, helps consumers address nutrient deficiencies with its TRACE line of beverages and supplements. Sourced from deep within British Columbia’s Rocky Mountains, TRACE products are high in fulvic and humic minerals, providing an easily absorbed source of minerals such as iron, magnesium, calcium, potassium…

MondayJul 12, 2021 11:21 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Delists from CSE to Focus Efforts on Most Effective Drug Platform Outcomes

Lexaria Bioscience is a drug bioavailability platform developer intent on providing an effective oral administration alternative to smoking that duplicates the rapid assimilation benefits of inhalation without the lung-harmful effects The company’s DehydraTECH IP is being evaluated for concentration levels, tolerability and ability to transform partner drugs to oral solutions without incidentally creating new molecular entities Lexaria announced voluntary delisting from the Canadian Securities Exchange this month in order to focus its resources more effectively on its Nasdaq listing The company’s leadership recently interacted with investors in the Life Sciences Investor Forum virtual conference series and the company’s annual meeting…

ThursdayJul 08, 2021 11:55 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive Results From its Recent Animal Study on the Effectiveness of its DehydraTECH Drug Delivery Technology

Lexaria Bioscience Corp. announced positive results from its VIRAL-A20-2 study This study showed strong gains in delivery of the DehydraTECH-enabled remdesivir and ebastine among animals The success of this study shows the potential and commercial viability of Lexaria’s DehydraTECH In June 2021, Lexaria Bioscience (NASDAQ: LEXX) announced positive results from its VIRAL-A20-2 study that evaluated the effectiveness of DehydraTECH-enabled remdesivir and ebastine among animals. The results were strongly positive and demonstrated greater effectiveness than in Lexaria’s first antiviral drug study reported in December 2000. The research was a tolerability and pharmacokinetic (“PK”) study involving four groups of 10 animals each.…

WednesdayJul 07, 2021 11:59 am

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Positioning Itself to Compete in US Functional Beverage Market

“Forbes” article notes that $20 million Naturo Group acquisition creates ideal situation for BevCanna expansion BevCanna boasts one of most unique, diverse portfolios of beverage and natural health products within both cannabis, plant-based industries Combination of two Canadian beverage industry leaders unlocks significant potential for growth As Canadian cannabis company BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) expands its infused functional beverage business into the United States, its deliberate, transformative strategy has garnered a mention in a recent “Forbes” article. Titled “BevCanna Expands in the U.S. Infused Functional Beverage Market Upon Acquiring Naturo Group,” the article noted that the…

TuesdayJul 06, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) Announces Milestone in Antiviral Delivery Platform Testing

Drug delivery platform developer Lexaria Bioscience has been testing its patented technology in conjunction with antivirals Remdesivir and Ebastine during the past year to determine the potential for enhancing their effectiveness against the COVID-19 virus Early-stage testing has determined Lexaria’s technology — DehydraTECH — did not inhibit Remdesivir and Ebastine in their use against the virus DehydraTECH is a technology that helps drugs gain better bioavailability through effective introduction into patients’ bloodstreams The DehydraTECH platform has also shown great potential in enhancing hypertension medication and additional trials are ongoing Pharmaceutical use and bioavailability innovator Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX)…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 905.674.5977

Month: July 2021